← Eichor
Condition: Her2 Expressing Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Expressing

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
Phase 2 · 1 location(s) · Yonsei University · NCT06837792Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Phase 1/Phase 2 · 11 location(s) · Vironexis Biotherapeutics Inc. · NCT07192432DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvan
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06389006HER2-PET Imaging in HER2-low Breast Cancers
Phase 1/Phase 2 · 1 location(s) · Centre de recherche du Centre hospitalier universitaire de S · NCT06732336Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladde
Phase 2 · 1 location(s) · Shanxi Province Cancer Hospital · NCT07646145Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Hutchmed · NCT07228247Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta
Phase 3 · 286 location(s) · AstraZeneca · NCT07431281Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer
Phase N/A · 1 location(s) · The Affiliated Hospital of Qingdao University · NCT06916637Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing So
Phase 1 · 7 location(s) · Myeloid Therapeutics · NCT07334119SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Phase 2 · 1 location(s) · Shenyang Sunshine Pharmaceutical Co., LTD. · NCT07022002Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07512583A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Ute
Phase 3 · 171 location(s) · BioNTech SE · NCT06340568Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3 · 75 location(s) · Daiichi Sankyo · NCT07022483A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Phase 1/Phase 2 · 166 location(s) · Pfizer · NCT06966453DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Phase 3 · 1 location(s) · Fudan University · NCT07207824To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Phase 2/Phase 3 · 2 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT06504732DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Tre
Phase 3 · 250 location(s) · AstraZeneca · NCT06989112Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06650332DESTINY Breast Respond HER2-(Ultra)Low Europe
Phase N/A · 211 location(s) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT05945732Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07670273Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06691035Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
Phase 1 · 6 location(s) · Myeloid Therapeutics · NCT05969041A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Phase 1 · 2 location(s) · Mayo Clinic · NCT04144023SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
Phase 2 · 1 location(s) · Shenyang Sunshine Pharmaceutical Co., LTD. · NCT07646626HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
Phase N/A · 1 location(s) · Renske Altena · NCT06830382
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.